The British government has ordered an investigation of Nvidia’s proposed US$40 billion acquisition of UK-headquartered chip designer Arm. The country’s competition regulator, the Competition and Markets Authority (CMA), will prepare an initial report on the takeover by the end of July, which will cover potential national security issues, as well as competition and jurisdictional issues created by the deal.
“I have today issued an intervention notice on national security grounds,” the UK’s digital secretary Oliver Dowden said in a statement. “The UK’s independent competition authority will now prepare a report on the implications of the transaction, which will help inform any further decisions.”
An Nvidia spokesperson told CNBC, “We do not believe this transaction poses any material national security issues. We will continue to work closely with the British authorities, as we have done since the announcement of this deal.”
Earlier this year, the CMA invited third parties to comment on the merger ahead of a formal antitrust investigation. That investigation will probe the deal’s possible effects on competition in the UK.
In February, US federal regulators opened an investigation into the purchase while soliciting information from third parties.
A consortium made up of Alphabet’s Google, Microsoft, and Qualcomm among others, reportedly asked antitrust officials to intervene in the sale, Bloomberg reported. At least one of the companies wants the deal “killed.”
Featured News
Top Antitrust Expert Joins Cravath from Paul Weiss
Jan 21, 2025 by
CPI
CMA Chief Removed as UK Government Targets Regulatory Overhaul
Jan 21, 2025 by
CPI
Court Denies Dismissal in Crab Price-Fixing Lawsuit
Jan 21, 2025 by
CPI
TikTok Stays Online for Now: Trump Floats US Ownership Deal
Jan 21, 2025 by
CPI
Hong Kong Watchdog Unveils Compliance Tool for Small Businesses
Jan 21, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Pharmacy Benefit Managers
Jan 20, 2025 by
CPI
Untangling the PBM Mess
Jan 20, 2025 by
Kent Bernard
Using Data, Not Anecdotes, to Analyze Criticisms of Pharmacy Benefit Managers
Jan 20, 2025 by
Dennis Carlton
Vertical Integration and PBMs: What, Me Worry?
Jan 20, 2025 by
Lawton Robert Burns & Bradley Fluegel
The Economics of Benefit Management in Prescription-Drug Markets
Jan 20, 2025 by
Casey B. Mulligan